(PharmaNewsWire.Com, February 19, 2020 ) Increasing prevalence of chronic diseases such as cancer and diabetes and favorable government policies for the pharmaceutical sector are the major factors driving the growth of Indian peptide market.
What the Market Looks Like? Predicted to grow at a CAGR of 4.9% during the forecast period, the global Indian Heparin market is estimated to reach USD 170.2 Million by the end of 2022.
“By type, hormonal segment is expected to dominate the market in 2016” On the basis of type segmentation, The Indian peptide drugs market is classified into hormonal, antifungal, antibiotic, ACE inhibitor and others. The hormonal segment is expected to dominate the Indian peptide drugs market in 2016.
“By application, the diabetes segment is expected to dominate the market in 2016” Based on application, the indian peptide drugs market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological application, and other applications. In 2016, the diabetes segment is expected to account for the largest share of the Indian peptide drugs market, by application.
Leading market players The prominent players in the Indian Heparin market include Abbott Laboratories (US), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
